Search results
Results from the WOW.Com Content Network
The treatment of latent tuberculosis infection (LTBI) is essential to controlling and eliminating TB by reducing the risk that TB infection will progress to disease. Latent tuberculosis will convert to active tuberculosis in 10% of cases (or more in cases of immune compromised patients).
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
The QuantiFERON-TB Gold blood test measures the patient's immune reactivity to the TB bacterium, and is useful for initial and serial testing of persons with an increased risk of latent or active tuberculosis infection. Guidelines for its use were released by the CDC in December 2005. [26]
[1] [9] People with latent TB do not spread the disease. [1] Active infection occurs more often in people with HIV/AIDS and in those who smoke. [1] Diagnosis of active TB is based on chest X-rays, as well as microscopic examination and culture of bodily fluids. [10] Diagnosis of latent TB relies on the tuberculin skin test (TST) or blood tests ...
Treatment of latent TB infection typically involves using a single drug for a prolonged period of time—the most common approach is Isoniazid for 9 months. Treatment of active TB disease is typically a combination of antibiotics, which results in patients being non-infectious to others usually within a few weeks.
The Quantiferon-TB Gold test (QFT-G) is a whole-blood test for use as an aid in diagnosing Mycobacterium tuberculosis infection, including latent tuberculosis infection (LTBI) and tuberculosis (TB) disease. [15] This test was approved by the U.S. Food and Drug Administration (FDA) in 2005.
According to a 2013 review, tuberculosis elimination will require not just treating active tuberculosis but also latent cases, and eliminating tuberculosis by 2050 worldwide is not possible, although great reductions in infections and deaths are possible. [3] Addressing poverty is a further requirement for eliminating tuberculosis.
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. [4] For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. [5] For latent tuberculosis, it is often used alone. [4]